MiNK Therapeutics, Inc. Common Stock
INKTMiNK Therapeutics, Inc. (INKT) is a biotechnology company focused on developing innovative immunotherapies and personalized treatments for cancer. The company leverages its proprietary technologies to enhance immune system responses, aiming to improve outcomes for patients with various types of malignancies.
Company News
MiNK Therapeutics presented clinical results showing promising immune cell therapy agenT-797 demonstrated durable responses and immune reactivation in patients with checkpoint-resistant solid tumors, with some patients experiencing complete remission lasting over two years.
MiNK Therapeutics reported a Q2 2025 net loss of $1.06 per share, with no revenue but promising clinical progress in iNKT cell therapies for cancer and immune diseases. The company raised $13 million in equity and continues advancing its lead product agenT-797 in clinical trials.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced its upcoming virtual Annual Shareholders Meeting and provided updates on its pipeline, including a NIAID grant for its allogeneic iNKT cell therapy for stem cell transplant patients and positive clinical data in various cancer indications.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that it will present interim data from its ongoing Phase 2 study testing AgenT-797 in combination with Agenus' botensilimab and balstilimab in patients with refractory gastric cancer.
MiNK Therapeutics presented data on a Phase 2 trial evaluating a combination of its iNKT cell therapy, Agenus' botensilimab and balstilimab, and standard chemotherapy in advanced gastroesophageal cancer patients. The novel combination demonstrated signals of tolerability and activity in this patient population.
